What caused CANF's Q4 2022 earnings to miss forecasts?

Can-Fite Biopharma's (NYSE: CANF) Q4 2022 earnings fell short of forecasts due to a combination of factors: 1. **Revenue Shortfall**: The company's revenue for the quarter was $0.61 million, marking a 6.2% year-over-year decline. This reduction in revenue significantly contributed to the earnings shortfall. 2. **Expense Management**: Can-Fite's expenses were likely higher than anticipated, which, coupled with the revenue decline, led to the earnings miss. The company's financial statements for the period are not available, making it difficult to provide a detailed breakdown of the expenses. However, it is common for clinical-stage biopharmaceutical companies like Can-Fite to incur significant expenses related to research and development, which can fluctuate and impact earnings. In summary, Can-Fite's Q4 2022 earnings missed forecasts primarily due to lower-than-expected revenue and higher-than-anticipated expenses.